Andrea Cercek
Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
12
all conditions, ClinicalTrials.gov
NIH grants tied to them
4
NIH RePORTER
Trial papers
21
PubMed author-name match
Trials
Studies that name Andrea Cercek as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:53 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06843434 · A Study of Botensilimab and Balstilimab for Rectal AdenocarcinomaMemorial Sloan Kettering Cancer Center · recruiting · Microsatellite Stable Rectal Carcinoma, Locally Advanced Rectal Adenocarcinoma · principal investigator
- Ph2NCT05672524 · A Study of Tucatinib and Trastuzumab in People With Rectal CancerMemorial Sloan Kettering Cancer Center · recruiting · Adenocarcinoma of the Rectum, Locally Advanced Rectal Adenocarcinoma, Rectal Adenocarcinoma · principal investigator
- N/ANCT05568420 · A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)Memorial Sloan Kettering Cancer Center · active not recruiting · Colorectal Cancer · principal investigator
- Ph2NCT04891289 · Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With SurgeryMemorial Sloan Kettering Cancer Center · recruiting · Intrahepatic Cholangiocarcinoma · principal investigator
- N/ANCT04812912 · Changes in Reproductive and Sexual Health in People With Early Onset Colorectal CancerMemorial Sloan Kettering Cancer Center · recruiting · Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma · principal investigator
- N/ANCT04489238 · Collection of Information to Better Understand Young Onset Colorectal CancerMemorial Sloan Kettering Cancer Center · recruiting · Colorectal Cancer, Colorectal Carcinoma · principal investigator
- Ph2NCT04165772 · Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid TumorsMemorial Sloan Kettering Cancer Center · recruiting · Rectal Adenocarcinoma, Clinical Stage: Stage II (T3-4, N-), Stage III (Any T, N+) · principal investigator
- Ph2NCT03069950 · Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the LiverMemorial Sloan Kettering Cancer Center · withdrawn · Colorectal Adenocarcinoma Metastatic to the Liver · principal investigator
- Ph2NCT02023333 · Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal AdenocarcinomaMemorial Sloan Kettering Cancer Center · completed · Metastatic Colorectal Adenocarcinoma · principal investigator
- Ph1NCT01938729 · Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic CholangiocarcinomaMemorial Sloan Kettering Cancer Center · completed · Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma, Cholangiolar Carcinoma · principal investigator
- Ph1NCT01281592 · A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid TumoursAptose Biosciences Inc. · completed · Advanced or Metastatic Solid Tumours · principal investigator
- Ph2NCT01111838 · Clinical and Translational Study of STA-9090Memorial Sloan Kettering Cancer Center · completed · Colon Cancer, Rectal Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal CancerR01CA288880 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2024 to 2026 · $402,600 awarded in 2026Same name and institution; not confirmed by an ID
- Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancerU01CA271287 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2022 to 2025 · $1,224,361 awarded in 2025Same name and institution; not confirmed by an ID
- Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)U01CA238444 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2020 to 2024 · $623,923 awarded in 2024Same name and institution; not confirmed by an ID
- Neoadjuvant PD-1 blockade in mismatch repair deficient rectal cancerR21CA252519 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2021 to 2022 · $202,732 awarded in 2022Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:53 UTC. The ranking covers the 200 most relevant of 21 PubMed records, and a shared surname and initials can bring in a namesake. All 21 on PubMed
- PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.N Engl J Med · 20221,341 citationsRCR 92.5
- Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.J Clin Oncol · 2022830 citationsRCR 71.5
- Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial.J Clin Oncol · 2024329 citationsRCR 55.3
- Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.J Clin Oncol · 2014302 citationsRCR 9.9
- 220 citationsRCR 18.8
- 194 citationsRCR 9.5
- Nonoperative Management of Mismatch Repair-Deficient Tumors.N Engl J Med · 2025193 citationsRCR 40.4
- 182 citationsRCR 6.8
- Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia.J Clin Oncol · 201998 citationsRCR 4.5
- 94 citationsRCR 4.0